Ligand-engineered biomimetic nanoparticles targeting the Achilles’ heel of NSCLC for synergistic photodynamic-immunotherapy

Non‑small cell lung cancer (NSCLC) remains refractory to most current therapeutic modalities, largely owing to poor target specificity and inadequate antitumor immune activation. To address these challenges, integrative analysis of single-cell RNA sequencing data and human lung cancer tissue microarrays identified elevated expression of adhesion G protein-coupled receptor F5 (ADGRF5) in NSCLC cells, highlighting its potential as a ligand-addressable target for tumor-selective nanomedicine delivery. Based on this finding, we leveraged fibronectin type III domain‑containing protein 4 (FNDC4), a previously identified high-affinity ligand of ADGRF5. We then constructed FNDC4-displaying biomimetic nanoparticles (termed PLACE@MF) by encapsulating the photosensitizer chlorin e6 (Ce6) and atractylenolide I (ATT‑I) into Poly(lactic‑co‑glycolic acid) (PLGA) cores, and further camouflaging the particles with cell membranes engineered to overexpress FNDC4. Leveraging the ligand-receptor interaction between FNDC4 and ADGRF5, the nanoparticles exhibited markedly enhanced specificity toward NSCLC cells both in vitro and in vivo. Upon light irradiation, Ce6‑mediated photodynamic therapy was able to kill the lung cancer cells directly and trigger immunogenic cell death. Concurrently, ATT‑I upregulated major histocompatibility complex class I (MHC‑I) expression on NSCLC cells, thereby potentiating CD8⁺ T‑cell‑mediated cytotoxicity. In NSCLC tumor‑bearing mouse models, PLACE@MF demonstrated superior therapeutic efficacy, reducing tumor volume to approximately one‑fifteenth of that in the control group. Collectively, this work establishes a ligand-receptor‑based targeting strategy via FNDC4-ADGRF5 axis and offers a promising framework for precision therapy of NSCLC.

Authors

Institutions

Publication Details

Journal
Journal of Nanobiotechnology
Published
2026-11-18
DOI
https://doi.org/10.1186/s12951-026-05270-9
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ligand-engineered biomimetic nanoparticles targeting the Achilles’ heel of NSCLC for synergistic photodynamic-immunotherapy

Yinshan Lin, Lingmin Zhang, Jiaqi Tian, Xiaoling Guan et al.
3 links
Journal of Nanobiotechnology
Nanoplatforms for cancer theranostics
article

Ligand-engineered biomimetic nanoparticles targeting the Achilles’ heel of NSCLC for synergistic photodynamic-immunotherapy

Yinshan Lin, Lingmin Zhang, Jiaqi Tian, Xiaoling Guan, Qingjun Yang, Juyan Wei, Songpei Li, Yingpeng Li, Siqi Yang, Qiuyun Liu
article en

Abstract

Non‑small cell lung cancer (NSCLC) remains refractory to most current therapeutic modalities, largely owing to poor target specificity and inadequate antitumor immune activation. To address these challenges, integrative analysis of single-cell RNA sequencing data and human lung cancer tissue microarrays identified elevated expression of adhesion G protein-coupled receptor F5 (ADGRF5) in NSCLC cells, highlighting its potential as a ligand-addressable target for tumor-selective nanomedicine delivery. Based on this finding, we leveraged fibronectin type III domain‑containing protein 4 (FNDC4), a previously identified high-affinity ligand of ADGRF5. We then constructed FNDC4-displaying biomimetic nanoparticles (termed PLACE@MF) by encapsulating the photosensitizer chlorin e6 (Ce6) and atractylenolide I (ATT‑I) into Poly(lactic‑co‑glycolic acid) (PLGA) cores, and further camouflaging the particles with cell membranes engineered to overexpress FNDC4. Leveraging the ligand-receptor interaction between FNDC4 and ADGRF5, the nanoparticles exhibited markedly enhanced specificity toward NSCLC cells both in vitro and in vivo. Upon light irradiation, Ce6‑mediated photodynamic therapy was able to kill the lung cancer cells directly and trigger immunogenic cell death. Concurrently, ATT‑I upregulated major histocompatibility complex class I (MHC‑I) expression on NSCLC cells, thereby potentiating CD8⁺ T‑cell‑mediated cytotoxicity. In NSCLC tumor‑bearing mouse models, PLACE@MF demonstrated superior therapeutic efficacy, reducing tumor volume to approximately one‑fifteenth of that in the control group. Collectively, this work establishes a ligand-receptor‑based targeting strategy via FNDC4-ADGRF5 axis and offers a promising framework for precision therapy of NSCLC.

Journal of Nanobiotechnology
Tianjin University of Traditional Chinese Medicine (CN), State Key Laboratory of Respiratory Disease (CN), Guangzhou Medical University (CN)
Guangzhou Medical University, National Natural Science Foundation of China
Good health and well-being
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon